Literature DB >> 350557

Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.

R C Heel, R N Brogden, T M Speight, G S Avery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 350557     DOI： 10.2165/00003495-197815060-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  23 in total

1.  Lipid lowering drugs and coronary heart disease.

Authors:  P J Scott
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs.

Authors:  F N Marshall; J E Lewis
Journal:  Toxicol Appl Pharmacol       Date:  1973-04       Impact factor: 4.219

3.  The effect of [4,4'-(isopropylidenethio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjects.

Authors:  J W Drake; R H Bradford; M McDearmon; R H Furman
Journal:  Metabolism       Date:  1969-11       Impact factor: 8.694

4.  Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol).

Authors:  J W Barnhart; J A Sefranka; D D McIntosh
Journal:  Am J Clin Nutr       Date:  1970-09       Impact factor: 7.045

5.  Influence of 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on experimental atherosclerosis in rabbits.

Authors:  D Kritchevsky; H K Kim; S A Tepper
Journal:  Proc Soc Exp Biol Med       Date:  1971-04

6.  Newer hypolipidemic agents.

Authors:  D Kritchevsky
Journal:  Fed Proc       Date:  1971 May-Jun

7.  [Action of the new hypocholesteremic agent DH-581 (dithiobisphenol) in humans].

Authors:  O J Brusco; M A Oriozabala; R Arakaki
Journal:  Prensa Med Argent       Date:  1971-10-08

8.  Effect of probucol in hyperlipidemic patients during two years of administration.

Authors:  W B Parsons
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

9.  Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.

Authors:  A F Salel; R Zelis; H S Sodhi; J Price; D T Mason
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

10.  An overview of the biochemical pharmacology of probucol.

Authors:  J W Barnhart; D J Rytter; J A Molello
Journal:  Lipids       Date:  1977-01       Impact factor: 1.880
View more
  9 in total

Review 1.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

2.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

3.  Probucol and hypercholesterolaemia.

Authors:  M C Bateson; A M Fiabane; A Clarke; I A Bouchier
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

Review 4.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 5.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb

6.  Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells.

Authors:  Aslı Koç; Arzu Zeynep Karabay; Ali Yaprak; Zeliha Büyükbingöl; Fügen Aktan
Journal:  Turk J Pharm Sci       Date:  2021-02-25

7.  Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation.

Authors:  Xianyi Sha; Juan Wu; Yanzuo Chen; Xiaoling Fang
Journal:  Int J Nanomedicine       Date:  2012-02-10

8.  Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study).

Authors:  Virginie Lam; Roger Clarnette; Roslyn Francis; Michael Bynevelt; Gerald Watts; Leon Flicker; Carolyn F Orr; Poh Loh; Nicola Lautenschlager; Christopher M Reid; Jonathan K Foster; Satvinder S Dhaliwal; Suzanne Robinson; Emily Corti; Mauro Vaccarezza; Ben Horgan; Ryusuke Takechi; John Mamo
Journal:  BMJ Open       Date:  2022-02-21       Impact factor: 2.692

9.  An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.

Authors:  Armin Mooranian; Rebecca Negrulj; Nigel Chen-Tan; Gerald F Watts; Frank Arfuso; Hani Al-Salami
Journal:  Drug Des Devel Ther       Date:  2014-09-29       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.